JP2017526742A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526742A5 JP2017526742A5 JP2017527980A JP2017527980A JP2017526742A5 JP 2017526742 A5 JP2017526742 A5 JP 2017526742A5 JP 2017527980 A JP2017527980 A JP 2017527980A JP 2017527980 A JP2017527980 A JP 2017527980A JP 2017526742 A5 JP2017526742 A5 JP 2017526742A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fragments
- optionally
- fragments derived
- tuberculosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 27
- 238000000034 method Methods 0.000 claims 16
- 108090000623 proteins and genes Proteins 0.000 claims 15
- 102000004169 proteins and genes Human genes 0.000 claims 15
- 230000028993 immune response Effects 0.000 claims 10
- 201000008827 tuberculosis Diseases 0.000 claims 8
- 238000000338 in vitro Methods 0.000 claims 6
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims 4
- 101100211638 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Rv2654c gene Proteins 0.000 claims 3
- 210000002865 immune cell Anatomy 0.000 claims 3
- 230000028327 secretion Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000036755 cellular response Effects 0.000 claims 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 101001057048 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) ESAT-6-like protein EsxB Proteins 0.000 claims 1
- 230000024932 T cell mediated immunity Effects 0.000 claims 1
- 230000006052 T cell proliferation Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BG11180414 | 2014-08-15 | ||
| BG111804 | 2014-08-15 | ||
| BG11204515 | 2015-06-30 | ||
| BG112045 | 2015-06-30 | ||
| PCT/GB2015/052362 WO2016024129A1 (en) | 2014-08-15 | 2015-08-14 | Mycobacterium tuberculosis proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020140576A Division JP2020198886A (ja) | 2014-08-15 | 2020-08-24 | 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ ｔｕｂｅｒｃｕｌｏｓｉｓ）タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526742A JP2017526742A (ja) | 2017-09-14 |
| JP2017526742A5 true JP2017526742A5 (enExample) | 2018-09-20 |
| JP6781698B2 JP6781698B2 (ja) | 2020-11-04 |
Family
ID=53969374
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017527980A Active JP6781698B2 (ja) | 2014-08-15 | 2015-08-14 | 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ ｔｕｂｅｒｃｕｌｏｓｉｓ）タンパク質 |
| JP2020140576A Pending JP2020198886A (ja) | 2014-08-15 | 2020-08-24 | 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ ｔｕｂｅｒｃｕｌｏｓｉｓ）タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020140576A Pending JP2020198886A (ja) | 2014-08-15 | 2020-08-24 | 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ ｔｕｂｅｒｃｕｌｏｓｉｓ）タンパク質 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10295538B2 (enExample) |
| EP (1) | EP3180353B1 (enExample) |
| JP (2) | JP6781698B2 (enExample) |
| CN (1) | CN107110862B (enExample) |
| ES (1) | ES2897933T3 (enExample) |
| WO (1) | WO2016024129A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106442983B (zh) * | 2016-08-31 | 2018-07-03 | 中国疾病预防控制中心传染病预防控制所 | 结核分枝杆菌抗原蛋白Rv3793及其T细胞表位肽的应用 |
| CN106248936B (zh) * | 2016-08-31 | 2018-09-25 | 中国疾病预防控制中心传染病预防控制所 | 结核分枝杆菌抗原蛋白Rv2201及其T细胞表位肽的应用 |
| CN112020555B (zh) * | 2018-05-02 | 2024-06-21 | 国立大学法人新潟大学 | 肽及其应用 |
| CN116348767A (zh) | 2020-10-06 | 2023-06-27 | 西菲伊德公司 | 诊断结核病以及区分活动性和潜伏性结核病的方法 |
| GB202101078D0 (en) * | 2021-01-27 | 2021-03-10 | Oxford Immunotec Ltd | Fragment pools |
| CN114736276B (zh) * | 2022-05-24 | 2023-08-01 | 中国人民解放军总医院第八医学中心 | 结核分枝杆菌ltbi-rd相关蛋白抗原的ctl表位肽及其应用 |
| CN115957312A (zh) * | 2023-01-17 | 2023-04-14 | 武汉大学 | B4galt1在制备抗结核分枝杆菌感染的药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002314358C1 (en) * | 2001-07-04 | 2009-03-26 | The Secretary Of State For Health | Mycobacterial antigens expressed during latency |
| WO2004099771A1 (en) * | 2003-05-08 | 2004-11-18 | Statens Serum Institut | A new specific epitope based immunological diagnosis of tuberculosis |
| ITRM20040091A1 (it) * | 2004-02-19 | 2004-05-19 | Istituto Naz Per Le Malattie | Test immunologico rapido per la diagnosi ed il monitoraggio dell'infezione tubercolare. |
| GB0406271D0 (en) | 2004-03-19 | 2004-04-21 | Isis Innovation | Diagnostic test |
| WO2006000045A1 (en) * | 2004-06-25 | 2006-01-05 | Proteome Systems Intellectual Property Pty Ltd | Novel methods of diagnosis and treatment of m. tuberculosis infection and reagents therefor i |
| WO2007131293A1 (en) * | 2006-05-16 | 2007-11-22 | Proteome Systems Limited | Methods of diagnosis and treatment of m. tuberculosis infection and reagents therefor vi |
| US7776341B2 (en) | 2006-08-10 | 2010-08-17 | Colorado State University Research Foundation | Biomarkers of tuberculosis that distinguish disease categories: use as serodiagnostic antigens |
| SI2315834T1 (sl) * | 2008-07-25 | 2018-09-28 | Glaxosmithkline Biologicals S.A. | Tuberkulozni Rv2386c protein, sestavki in njegove uporabe |
| WO2010132054A1 (en) * | 2009-05-13 | 2010-11-18 | Immport Therapeutics, Inc. | Compositions and methods for immunodominant antigens of mycobacterium tuberculosis |
| CN103884847B (zh) | 2014-03-14 | 2015-08-26 | 中国科学院生物物理研究所 | 一种结核分枝杆菌全蛋白质芯片及应用 |
-
2015
- 2015-08-14 WO PCT/GB2015/052362 patent/WO2016024129A1/en not_active Ceased
- 2015-08-14 EP EP15753982.6A patent/EP3180353B1/en active Active
- 2015-08-14 ES ES15753982T patent/ES2897933T3/es active Active
- 2015-08-14 JP JP2017527980A patent/JP6781698B2/ja active Active
- 2015-08-14 CN CN201580056106.6A patent/CN107110862B/zh active Active
- 2015-08-14 US US15/503,151 patent/US10295538B2/en active Active
-
2020
- 2020-08-24 JP JP2020140576A patent/JP2020198886A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526742A5 (enExample) | ||
| TWI638829B (zh) | 分枝桿菌抗原疫苗 | |
| RU2695462C2 (ru) | Гибридизация гетероолигомерных микобактериальных антигенов | |
| Vordermeier et al. | Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis | |
| EP2912056B1 (en) | M. tuberculosis vaccines | |
| Geluk et al. | Innovative strategies to identify M. tuberculosis antigens and epitopes using genome-wide analyses | |
| Tiwari et al. | An immunomodulatory role for the M ycobacterium tuberculosis region of difference 1 locus proteins PE 35 (R v3872) and PPE 68 (R v3873) | |
| Liu et al. | A multistage mycobacterium tuberculosis subunit vaccine LT70 including latency antigen Rv2626c induces long-term protection against tuberculosis | |
| SA517380842B1 (ar) | بروتينات دمج لمستقبل إنترليوكين-2/إنترليوكين-2 ألفا وطرق الاستخدام | |
| Coppola et al. | Vaccines for leprosy and tuberculosis: opportunities for shared research, development, and application | |
| Santoro et al. | Transcriptomics of the vaccine immune response: priming with adjuvant modulates recall innate responses after boosting | |
| US10004793B2 (en) | M.tuberculosis vaccines | |
| Geluk et al. | A multistage-polyepitope vaccine protects against Mycobacterium tuberculosis infection in HLA-DR3 transgenic mice | |
| Counoupas et al. | Mycobacterium tuberculosis components expressed during chronic infection of the lung contribute to long-term control of pulmonary tuberculosis in mice | |
| JP2016508143A5 (enExample) | ||
| Maybeno et al. | Polyfunctional CD4+ T cell responses to immunodominant epitopes correlate with disease activity of virulent Salmonella | |
| Leung-Theung-Long et al. | A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis | |
| Wang et al. | Evaluation of a recombinant BCG expressing antigen Ag85B and PPE protein Rv3425 from DNA segment RD11 of Mycobacterium tuberculosis in C57BL/6 mice | |
| Seidel et al. | BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA. 1 in young adults | |
| Kong et al. | A novel vaccine p846 encoding Rv3615c, Mtb10. 4, and Rv2660c elicits robust immune response and alleviates lung injury induced by Mycobacterium infection | |
| JP2014501747A (ja) | ワクチンとしての組み換えマイコバクテリウム | |
| Hu et al. | A multistage Sendai virus vaccine incorporating latency-associated antigens induces protection against acute and latent tuberculosis | |
| Wang et al. | PPE protein (Rv3425) from DNA segment RD11 of Mycobacterium tuberculosis: a novel immunodominant antigen of Mycobacterium tuberculosis induces humoral and cellular immune responses in mice | |
| WO2016077525A3 (en) | Human anti-thyroglobulin t cell receptors | |
| JP2021503276A5 (enExample) |